Latest filing published 01 Apr 2022 for Monopar Therapeutics.
Insider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Andrew Paul Mazar: trading record in brief
All filings by Andrew Paul Mazar on record concern Monopar Therapeutics, in the capacity of senior executive. The record holds 12 filings, for trades running from 1 January 2021 to 31 March 2022.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
The newest entry dates from 1 April 2022: a share grant of €1,085, in Monopar Therapeutics. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. US insiders must file a Form 4 within two business days of a trade. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Andrew Paul Mazar
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 1,606 sharesCommon StockSEC:0001654954-22-004490:0
- 1,937 sharesCommon StockSEC:0001654954-22-000130:0
- 1,606 sharesCommon StockSEC:0001654954-22-000129:0
- 1,606 sharesCommon StockSEC:0001654954-21-010720:0
- 3,212 sharesCommon StockSEC:0001654954-21-007595:0
5 of 5 declarations
